Skip to main content
. 2025 Apr 10;2025:2702089. doi: 10.1155/cjgh/2702089

Figure 4.

Figure 4

Secondary endpoint; cure rate of erosion. (a) FAS. A: CKD-495 75 mg vs placebo (p=0.0075), B: CKD-495 75 mg vs. Stillen 60 mg (p=0.0101), C: CKD-495 75 mg vs Rebamipide 100 mg (p=0.0052), D: CKD-495 150 mg vs. Placebo (p=0.8737), E: CKD-495 150 mg vs. Stillen 60 mg (p=0.7830), F: CKD-495 150 mg vs. Rebamipide 100 mg (p=0.9674). (b) PPS, A: CKD-495 75 mg vs. placebo (p=0.0054), B: CKD-495 75 mg vs. Stillen 60 mg (p=0.0053), C: CKD-495 75 mg vs. Rebamipide 100 mg (p=0.0073), D: CKD-495 150 mg vs. Placebo (p=0.5933), E: CKD-495 150 mg vs. Stillen 60 mg (p=0.6207), F: CKD-495 150 mg vs. Rebamipide 100 mg (p=0.6156).